Treatment of detrusor instability with oxybutynin rectal suppositories
- PMID: 9694139
- DOI: 10.1007/BF01982217
Treatment of detrusor instability with oxybutynin rectal suppositories
Abstract
Our aim was to determine whether oxybutynin hydrochloride suppositories can be used as a treatment for detrusor instability in patients who have not been able to tolerate oral pharmacological agents. A retrospective chart review of 25 women diagnosed with detrusor instability and treated with oxybutynin rectal suppositories was conducted. Each suppository contained 5 mg oxybutynin, 15 mg micronized Sila gel, and 1.25 g of a fatty acid base. Patients were started on one suppository twice daily and then dose titrated as tolerated. The range of the total daily dose was 5-20 mg. Nine of 25 women (36%) had greater than a 50% overall subjective improvement and 3 (12%) had some improvement. Seven of the 12 responders (58%) continued to use the suppositories for a prolonged period of time (> 90 days). The most common side effects reported were dry mouth 48% and constipation 14.3%. One patient with polymyositis developed a serious anticholinergic reaction which required hospitalization. It was concluded that patients who are unable to tolerate oral anticholinergic and antispasmodic agents for the treatment of detrusor instability may benefit from oxybutynin rectal suppositories.
Similar articles
-
[Therapeutic effects of intrarectal administration of oxybutynin].Wiad Lek. 2002;55(11-12):691-8. Wiad Lek. 2002. PMID: 12715351 Polish.
-
Advances in anticholinergic therapy delivery systems.Geriatrics. 2002 May;57 Suppl 1:29-34. Geriatrics. 2002. PMID: 12040601 No abstract available.
-
An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.Clin Ther. 1999 Apr;21(4):634-42. doi: 10.1016/S0149-2918(00)88316-2. Clin Ther. 1999. PMID: 10363730 Review.
-
Intravesical oxybutynin: practicalities of clinical use.J Obstet Gynaecol. 2006 Feb;26(2):141-3. doi: 10.1080/01443610500443477. J Obstet Gynaecol. 2006. PMID: 16483973
-
Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor.BJU Int. 2001 Jun;87(9):767-73. doi: 10.1046/j.1464-410x.2001.02227.x. BJU Int. 2001. PMID: 11412211 Review. No abstract available.
Cited by
-
Urinary incontinence: oxybutynin topical gel for overactive bladder.Nat Rev Urol. 2009 Jul;6(7):351-2. doi: 10.1038/nrurol.2009.111. Nat Rev Urol. 2009. PMID: 19578347 No abstract available.
-
The evolution of transdermal therapy for overactive bladder.Curr Urol Rep. 2009 Sep;10(5):338-41. doi: 10.1007/s11934-009-0053-4. Curr Urol Rep. 2009. PMID: 19709479
-
Anticholinergiques et hyperactivité vésicale.Can Urol Assoc J. 2014 Jan;8(1-2):E36-43. doi: 10.5489/cuaj.1450. Can Urol Assoc J. 2014. PMID: 24454599 Free PMC article. Review. French.
-
Clinical utility of transdermal delivery of oxybutynin gel via a metered-dose pump in the management of overactive bladder.Res Rep Urol. 2012 Nov 27;4:57-64. doi: 10.2147/RRU.S28943. eCollection 2012. Res Rep Urol. 2012. PMID: 24199182 Free PMC article. Review.
-
Management of overactive bladder with transdermal oxybutynin.Rev Urol. 2006 Summer;8(3):93-103. Rev Urol. 2006. PMID: 17043706 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical